JP4498745B2 - ピリミジノンウイルスポリメラーゼ阻害剤 - Google Patents
ピリミジノンウイルスポリメラーゼ阻害剤 Download PDFInfo
- Publication number
- JP4498745B2 JP4498745B2 JP2003562091A JP2003562091A JP4498745B2 JP 4498745 B2 JP4498745 B2 JP 4498745B2 JP 2003562091 A JP2003562091 A JP 2003562091A JP 2003562091 A JP2003562091 A JP 2003562091A JP 4498745 B2 JP4498745 B2 JP 4498745B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxo
- dihydropyrimidine
- hydroxy
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *CC(CC(*)=N)=CO Chemical compound *CC(CC(*)=N)=CO 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0201179.9A GB0201179D0 (en) | 2002-01-18 | 2002-01-18 | Therapeutic agents |
| PCT/GB2003/000124 WO2003062211A1 (en) | 2002-01-18 | 2003-01-15 | Pyrimidinone viral polymerase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005524627A JP2005524627A (ja) | 2005-08-18 |
| JP2005524627A5 JP2005524627A5 (cg-RX-API-DMAC7.html) | 2010-02-04 |
| JP4498745B2 true JP4498745B2 (ja) | 2010-07-07 |
Family
ID=9929352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003562091A Expired - Fee Related JP4498745B2 (ja) | 2002-01-18 | 2003-01-15 | ピリミジノンウイルスポリメラーゼ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050130997A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1470113B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4498745B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE420078T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2473508A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60325692D1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0201179D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003062211A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004062613A2 (en) | 2003-01-13 | 2004-07-29 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| ATE478886T1 (de) | 2003-07-25 | 2010-09-15 | Idenix Pharmaceuticals Inc | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c |
| WO2005016384A1 (ja) * | 2003-08-13 | 2005-02-24 | Bf Research Institute, Inc. | アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤 |
| AR046938A1 (es) * | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| CN1922174A (zh) | 2004-02-20 | 2007-02-28 | 贝林格尔·英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| AU2006242475B2 (en) | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| JP5094725B2 (ja) * | 2005-10-04 | 2012-12-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Hivインテグラーゼ阻害剤 |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| CN101583372A (zh) | 2006-10-24 | 2009-11-18 | 默克公司 | Hcv ns3蛋白酶抑制剂 |
| CA2667165A1 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| WO2008057208A2 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| JP5268927B2 (ja) | 2006-10-27 | 2013-08-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvns3プロテアーゼ阻害剤 |
| US8101595B2 (en) | 2006-12-20 | 2012-01-24 | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA | Antiviral indoles |
| GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| MX2009011930A (es) | 2007-05-04 | 2009-11-18 | Vertex Pharma | Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c. |
| US7763630B2 (en) | 2007-06-06 | 2010-07-27 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| AU2008277442A1 (en) | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis C infections |
| CN101754974B (zh) | 2007-07-19 | 2016-02-03 | Msd意大利有限公司 | 作为抗病毒剂的大环化合物 |
| WO2009018657A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| CN102014911A (zh) | 2008-04-28 | 2011-04-13 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
| ES2392611T3 (es) | 2008-07-22 | 2012-12-12 | Merck Sharp & Dohme Corp. | Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC |
| KR20110116136A (ko) | 2009-01-07 | 2011-10-25 | 싸이넥시스, 인크. | Hcv 및 hiv 감염의 치료에 사용하기 위한 사이클로스포린 유도체 |
| AU2010210426B2 (en) * | 2009-02-06 | 2015-06-11 | Imago Pharmaceuticals, Inc. | Inhibitors of Jun N-terminal kinase |
| US8143244B2 (en) | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| RU2552533C2 (ru) * | 2009-03-25 | 2015-06-10 | Эббви Инк. | Противовирусные соединения и их применения |
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| US8383639B2 (en) | 2009-10-15 | 2013-02-26 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| RU2572835C2 (ru) * | 2010-08-13 | 2016-01-20 | Ф. Хоффманн-Ля Рош Аг | Производные (4-метилсульфониламинофенил)-хинолина, полезные при лечении гепатита с |
| WO2012151567A1 (en) * | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2260319B (en) * | 1991-10-07 | 1995-12-06 | Norsk Hydro As | Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity |
| DE19817265A1 (de) * | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| WO2000013708A1 (en) * | 1998-09-04 | 2000-03-16 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
| GB0017676D0 (en) * | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
-
2002
- 2002-01-18 GB GBGB0201179.9A patent/GB0201179D0/en not_active Ceased
-
2003
- 2003-01-15 CA CA002473508A patent/CA2473508A1/en not_active Abandoned
- 2003-01-15 DE DE60325692T patent/DE60325692D1/de not_active Expired - Lifetime
- 2003-01-15 US US10/500,971 patent/US20050130997A1/en not_active Abandoned
- 2003-01-15 JP JP2003562091A patent/JP4498745B2/ja not_active Expired - Fee Related
- 2003-01-15 EP EP03700366A patent/EP1470113B1/en not_active Expired - Lifetime
- 2003-01-15 WO PCT/GB2003/000124 patent/WO2003062211A1/en not_active Ceased
- 2003-01-15 AT AT03700366T patent/ATE420078T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2473508A1 (en) | 2003-07-31 |
| GB0201179D0 (en) | 2002-03-06 |
| EP1470113A1 (en) | 2004-10-27 |
| DE60325692D1 (de) | 2009-02-26 |
| WO2003062211A1 (en) | 2003-07-31 |
| US20050130997A1 (en) | 2005-06-16 |
| EP1470113B1 (en) | 2009-01-07 |
| ATE420078T1 (de) | 2009-01-15 |
| JP2005524627A (ja) | 2005-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005524627A (ja) | ピリミジノンウイルスポリメラーゼ阻害剤 | |
| EP1309566B1 (en) | Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors | |
| US20080200513A1 (en) | Pyridine N-Oxides As Antiviral Agents | |
| AU2008206441B2 (en) | N-substituted glycine derivatives: hydroxylase inhibitors | |
| AU2003265348B2 (en) | Thiophene compounds | |
| AU2001272530A1 (en) | Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors | |
| KR101891933B1 (ko) | B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 피리다존 및 트라이아진온 | |
| JP6441315B2 (ja) | スルファモイルチオフェンアミド誘導体およびb型肝炎を治療するための医薬品としてのその使用 | |
| US20040229889A1 (en) | HDAC inhibitor | |
| JP2004521944A (ja) | H.pylori感染症を阻害する新規ピラゾロ[3,4−d]ピリミジン類 | |
| TW201443027A (zh) | 抗感染劑及其用途 | |
| US6337342B1 (en) | Bis-aryl or heteroaryl indoles | |
| JP2017512796A (ja) | 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用 | |
| WO2021121420A1 (zh) | 苯并吡唑类化合物及其中间体、制备方法和应用 | |
| JPH09509957A (ja) | 免疫調節剤としてのキノリン誘導体 | |
| JP2006117647A (ja) | ハロゲノピラゾロピリジンピリダジノン誘導体とその付加塩及びそれを有効成分とするpde阻害剤 | |
| AU2003201666A1 (en) | Pyrimidinone viral polymerase inhibitors | |
| US20120196915A1 (en) | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process | |
| UA81271C2 (en) | 2-pyridone derivatives as inhibitors of neutrophile elastase, process for the preparation thereof and pharmaceutical composition based thereon | |
| JPS5939877A (ja) | 新規なピリミドン誘導体及びその製造方法 | |
| MXPA00009418A (en) | PYRROLO[1,2-a]PYRAZINE sPLA2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090609 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090902 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090909 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091208 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20091208 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100330 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100414 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130423 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130423 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140423 Year of fee payment: 4 |
|
| LAPS | Cancellation because of no payment of annual fees |